| MeSH term | MeSH ID | Detail |
|---|---|---|
| Syphilis | D013587 | 6 associated lipids |
| Hearing Disorders | D006311 | 10 associated lipids |
| Encephalomyelitis, Autoimmune, Experimental | D004681 | 26 associated lipids |
| Infant, Newborn, Diseases | D007232 | 9 associated lipids |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | D054198 | 10 associated lipids |
| Uterine Cervicitis | D002575 | 3 associated lipids |
| Neutropenia | D009503 | 15 associated lipids |
| Lung Diseases, Obstructive | D008173 | 10 associated lipids |
| Urticaria | D014581 | 13 associated lipids |
| Escherichia coli Infections | D004927 | 17 associated lipids |
Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Waag DM | Efficacy of postexposure therapy against glanders in mice. | 2015 | Antimicrob. Agents Chemother. | pmid:25645854 |
| Nash KA and Inderlied CB | Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. | 1995 | Antimicrob. Agents Chemother. | pmid:8592991 |
| Bohte R et al. | Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia. | 1995 | Antimicrob. Agents Chemother. | pmid:8593024 |
| Kirkcaldy RD et al. | Analysis of Neisseria gonorrhoeae azithromycin susceptibility in the United States by the Gonococcal Isolate Surveillance Project, 2005 to 2013. | 2015 | Antimicrob. Agents Chemother. | pmid:25451056 |
| Nahata MC et al. | Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. | 1993 | Antimicrob. Agents Chemother. | pmid:8383944 |
| Vaara M | Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. | 1993 | Antimicrob. Agents Chemother. | pmid:8383945 |
| Brown ST et al. | Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine. | 1993 | Antimicrob. Agents Chemother. | pmid:8384809 |
| Goldman RC et al. | Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria. | 1990 | Antimicrob. Agents Chemother. | pmid:2159256 |
| Gladue RP and Snider ME | Intracellular accumulation of azithromycin by cultured human fibroblasts. | 1990 | Antimicrob. Agents Chemother. | pmid:2168141 |
| Koletar SL et al. | Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. | 1999 | Antimicrob. Agents Chemother. | pmid:10582873 |
| Nicolau DP et al. | Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model. | 1999 | Antimicrob. Agents Chemother. | pmid:10582906 |
| Conte JE et al. | Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. | 1996 | Antimicrob. Agents Chemother. | pmid:8807050 |
| Dagan R et al. | Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. | 2000 | Antimicrob. Agents Chemother. | pmid:10602721 |
| Sugie M et al. | Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. | 2004 | Antimicrob. Agents Chemother. | pmid:14982769 |
| McGannon CM et al. | Different classes of antibiotics differentially influence shiga toxin production. | 2010 | Antimicrob. Agents Chemother. | pmid:20585113 |
| Caceres SM et al. | Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. | 2014 | Antimicrob. Agents Chemother. | pmid:25182651 |
| Clark C et al. | In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. | 2002 | Antimicrob. Agents Chemother. | pmid:12183253 |
| den Hollander JG et al. | Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. | 1998 | Antimicrob. Agents Chemother. | pmid:9527789 |
| Bulman ZP et al. | Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin. | 2017 | Antimicrob. Agents Chemother. | pmid:28096154 |
| Blandizzi C et al. | Distribution of azithromycin in plasma and tonsil tissue after repeated oral administration of 10 or 20 milligrams per kilogram in pediatric patients. | 2002 | Antimicrob. Agents Chemother. | pmid:11959610 |
| Steele-Moore L et al. | In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. | 1999 | Antimicrob. Agents Chemother. | pmid:10383373 |
| Capobianco JO and Goldman RC | Erythromycin and azithromycin transport into Haemophilus influenzae ATCC 19418 under conditions of depressed proton motive force (delta mu H). | 1990 | Antimicrob. Agents Chemother. | pmid:2178338 |
| Geisler WM et al. | Randomized, double-blind, multicenter safety and efficacy study of rifalazil compared with azithromycin for treatment of uncomplicated genital Chlamydia trachomatis infection in women. | 2014 | Antimicrob. Agents Chemother. | pmid:24798277 |
| Galarza PG et al. | New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. | 2010 | Antimicrob. Agents Chemother. | pmid:20123998 |
| Hoppe JE and Bryskier A | In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). | 1998 | Antimicrob. Agents Chemother. | pmid:9559823 |
| Carryn S et al. | Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. | 2002 | Antimicrob. Agents Chemother. | pmid:12069960 |
| Babl FE et al. | Experimental acute otitis media due to nontypeable Haemophilus influenzae: comparison of high and low azithromycin doses with placebo. | 2002 | Antimicrob. Agents Chemother. | pmid:12069974 |
| Sahm DF et al. | Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. | 2001 | Antimicrob. Agents Chemother. | pmid:11257013 |
| Erhardt W et al. | Establishing criteria for assessment of efficacy of antimicrobial agents in acute otitis media. | 2000 | Antimicrob. Agents Chemother. | pmid:11012390 |
| Klemens SP and Cynamon MH | Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice. | 1994 | Antimicrob. Agents Chemother. | pmid:7986001 |
| Roblin PM et al. | In vitro activity of trovafloxacin against Chlamydia pneumoniae. | 1997 | Antimicrob. Agents Chemother. | pmid:9303410 |
| O'Reilly T et al. | Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin. | 1992 | Antimicrob. Agents Chemother. | pmid:1336342 |
| Nakajima T et al. | Microbiological and Clinical Effects of Sitafloxacin and Azithromycin in Periodontitis Patients Receiving Supportive Periodontal Therapy. | 2016 | Antimicrob. Agents Chemother. | pmid:26729495 |
| Ravdin JI and Skilogiannis J | In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole. | 1989 | Antimicrob. Agents Chemother. | pmid:2548442 |
| Liu P et al. | Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media. | 2011 | Antimicrob. Agents Chemother. | pmid:21859932 |
| Goldstein EJ et al. | Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates. | 1995 | Antimicrob. Agents Chemother. | pmid:7625795 |
| Sjölund-Karlsson M et al. | Antimicrobial susceptibility to azithromycin among Salmonella enterica isolates from the United States. | 2011 | Antimicrob. Agents Chemother. | pmid:21690279 |
| Viscardi RM et al. | Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose. | 2013 | Antimicrob. Agents Chemother. | pmid:23439637 |
| Agacfidan A et al. | In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. | 1993 | Antimicrob. Agents Chemother. | pmid:8239579 |
| Tomazic J et al. | In vivo administration of azithromycin affects lymphocyte activity in vitro. | 1993 | Antimicrob. Agents Chemother. | pmid:8239585 |
| Cantin L and Chamberland S | In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. | 1993 | Antimicrob. Agents Chemother. | pmid:8239619 |
| Imamura Y et al. | Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. | 2005 | Antimicrob. Agents Chemother. | pmid:15793115 |
| Shima K et al. | Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis. | 2011 | Antimicrob. Agents Chemother. | pmid:21321137 |
| Chinh NT et al. | Pharmacokinetics and ex vivo antimalarial activity of artesunate-azithromycin in healthy volunteers. | 2011 | Antimicrob. Agents Chemother. | pmid:21730120 |
| Karlowsky JA et al. | Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. | 2003 | Antimicrob. Agents Chemother. | pmid:12760850 |
| Kutlin A et al. | Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. | 2002 | Antimicrob. Agents Chemother. | pmid:11796350 |
| Alder JD et al. | Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. | 1998 | Antimicrob. Agents Chemother. | pmid:9736568 |
| Kosowska-Shick K et al. | Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis. | 2006 | Antimicrob. Agents Chemother. | pmid:17043120 |
| Phillips-Campbell R et al. | Induction of the Chlamydia muridarum stress/persistence response increases azithromycin treatment failure in a murine model of infection. | 2014 | Antimicrob. Agents Chemother. | pmid:24342653 |
| Jang MO et al. | Outcome of intravenous azithromycin therapy in patients with complicated scrub typhus compared with that of doxycycline therapy using propensity-matched analysis. | 2014 | Antimicrob. Agents Chemother. | pmid:24366734 |